First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study

Abstract

This phase II study assessed the safety and efficacy of oxaliplatin and capecitabine in patients with advanced oesophageal cancer. Fiftyone eligible patients received oxaliplatin 130 mg m À2 intravenously on day 1 and capecitabine 1000 mg m À2 orally twice daily on days 1 to 14 in a 21-day treatment cycle as first-line treatment for advanced oesophageal cancer. Grade 3 neutropenia was seen in one patient and anaemia in another patient. No grade 4 haematological toxicities were observed. Grade 4 non-haematological toxicity (lethargy) occurred in one patient (2%). Grade 3 non-haematological toxicity was seen in 14 (27%) patients (vomiting and polyneuropathy (8%); nausea (6%); lethargy and hand -foot syndrome (4%); and anorexia, diarrhoea, and hyperbilirubinaemia (each in one patient)). In 22% of the patients, toxicity was the reason for stopping the treatment. The overall response rate was 39%. The median overall survival was 8 months; the 1-year survival rate was 26%. In the quality of life (QoL) analysis, the emotional well-being improved during treatment, but the physical functioning scores declined. The fatigue score on the symptom scales increased. Overall, the global QoL score did not change during treatment. In conclusion, the activity of oxaliplatin and capecitabine is comparable with other chemotherapy regimens in advanced oesophageal cancer with a low frequency of grade 3/4 toxicity. Because this treatment can be given on an outpatient basis, it is probably less toxic than cisplatin-based therapy and preserves QoL during treatment, it is a viable treatment option in patients with advanced oesophageal cancer.

Individualized Chemotherapy for Metastatic Gastric Cancer: Retrospective Data from a University Hospital in Brazil

“…A phase III study reported 47.9% objective response for patients treated with EOX; this difference in outcomes may be explained by the difference in number of patients treated in each study (16 and 244, respectively) (Cunningham et al, 2008). Some phase II studies that evaluated the efficacy of treatment with two drugs reported an overall RR of 42% on average (range: 35% to 65%) that is consistent with the value obtained in this study (Jatoi et al, 2006;Park et al, 2006;Van Meerten et al, 2007). This study was not designed to compare various treatment protocols, so these findings must be analyzed carefully.…”

Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer

“…There are few reports about this protocol used in esophageal cancer [12,13] . As a result of different pathological types, there have been some reports about combined treatment of oxalipatin and capecitabine for esophageal adenocarcinoma.…”

Platinum Complexes with Edda (Ethylenediamine -N, N - Diacetate) Ligands as Potential Anticancer Agents

“…It has therefore been necessary to synthesize more selective and less reactive molecule. This led to platinum complexes of the second and third generation (28)(29)(30). Complexes of the second generation are structural analogs of cisplatin, designed to overcome the toxicity of cisplatin, while the third generation complexes were created as even more advanced analogues with the main task to act on tumor cells resistant to cisplatin.…”